Fungal respiratory disease.
OBJECTIVE
Fungal respiratory disease is associated with a high mortality in immunocompromised patients. This review aims to describe the recent advances in the aetiology, clinical presentation, diagnosis and management of fungal respiratory disease.


RESULTS
Invasive aspergillosis is an uncommon complication of hematopoietic stem cell transplants and solid-organ transplants but continues to be associated with poor outcome. Isolation of Aspergillus spp. from respiratory samples preceded acute rejection in lung-transplantation recipients. Molecular typing suggested that there was a very weak correlation between the environmental and patient isolates of Aspergillus fumigatus in invasive pulmonary aspergillosis. Serological and molecular detection of Aspergillus antigens or fungal DNA may improve the diagnosis of pulmonary aspergillosis, but the sensitivity is variable and more studies are needed. Voriconazole and caspofungin are choice to Aspergillus and Candida infection, especially to azole-resistant Candida spp. Treatment combining amphotericin B preparations, early surgical resection of infected tissue and discontinuation of immunosuppressive treatment may improve prognosis of mucormycosis.


CONCLUSIONS
Invasive filamentaous fungal infections of lung remain important causes of death in immunocompromised patients. Development of new early diagnostic tools and well-designed multicenter evaluations of diagnostic methods and therapeutic regimens available at present are the important work in the next 2-3 years.
Medical Mycology Laboratory, Shanghai Jiaotong University Xinhua Hospital, Shanghai, China. zryaosmu@sohu.com
Zhirong
Z
Yao
Wanqing
W
Liao
D000935:Antifungal Agents / Q000627:therapeutic use; D003937:Diagnosis, Differential; D006801:Humans; D009181:Mycoses / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology; D012141:Respiratory Tract Infections / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology
D000935:Antifungal Agents